Dear Shareholders,
I am delighted to share that in a year marked by macroeconomic
challenges, we have ensured resilient performance and strategically pursued our quest for
excellence. The current global economic landscape presents notable potential for growth
and innovation. Our expertise in the complex Active Pharmaceutical Ingredients (APIs) and
Formulation development empowers us to further strengthen a portfolio of balanced,
innovative and sustainable solutions.
We have strategically positioned ourselves in niche growth areas such
as Biologics, Transdermal and Oral Dissolving Films (ODFs) through an emphasis on advanced
research and development. Supported by our best-in-class manufacturing capabilities, we
ensure delivery of high-quality, affordable drugs, reinforcing our commitment to develop
patient-centric solutions.
Our strong R&D background, encompassing development, pathway
engineering, complex chemistry and characterisation of biologics, has led our way through
a complex pharmaceutical landscape. To further cement our position in a competitive
environment, we are focusing on our Contract Development and Manufacturing Organization
(CDMO) business to enhance our reach and fulfil the unmet patient needs.
Whilst we continue to remain steadfastly focused on delivering on our
oncology-API portfolio with addition of newer products, in the non- oncology API segment,
we are exploring products with high growth potential and aiming to offer indigenous
solutions that can substitute imports. Moreover, we continue our developmental efforts on
the niche areas of peptides and polymers to create our future growth engines.
We remain committed to move up the pharma value chain through an
emphasis on the Formulation business, specialising in complex Oncology and Non-Oncology
treatments. By facilitating the introduction of valueadded products, including Novel Drug
Delivery System (NDDS) products in the areas of orally disintegrating films and
transdermal patches with a focus on patient comfort and compliance Similarly in the
biological space, we strive to introduce products that provide better healthcare at
affordable cost including improved availability of life saving medicines.
We adhere to stringent environmental management system (EMS) standards,
focusing on waste management, adoption of renewable energy and inculcating safe practices
across the organisation. As a responsible corporate, we lay emphasis on Environmental,
Social and Governance (ESG) performance, along with extensive Corporate Social
Responsibility (CSR) initiatives that span across diverse fields, including education,
healthcare, the environment, and sports, reflecting our dedication to the holistic
well-being of the communities we serve.
I would like to thank our clients, business partners and esteemed
shareholders for their continued support. Moving ahead, we are determined to innovate,
excel and create value while ensuring sustainable and inclusive growth. With our strategic
focus and unwavering commitment, we are confident in achieving new milestones and
delivering on our promise of affordable and high-quality healthcare solutions.
Thank you for your continued trust and support.
Warm regards,
Omprakash Inani
Chairman